Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?
